Cost‐Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom
Once weekly rezafungin is a cost-saving and cost-effective treatment option in IC from the UK healthcare perspective.
Authors
- Neil Hawkins (ORCID: https://orcid.org/0000-0003-3199-221X)
- Keith R. Abrams (ORCID: https://orcid.org/0000-0002-7557-1567)
- S Dickerson
- I Bielicka
- M. Lebmeier (ORCID: https://orcid.org/0000-0002-5343-0122)
- Nick Manamley (ORCID: https://orcid.org/0009-0003-9325-0323)
- Alisha Angdembe
- N. Muszbek (ORCID: https://orcid.org/0000-0002-1236-1327)
- Markus Ruhnke (ORCID: https://orcid.org/0000-0002-0793-9729)
- Carolina García‐Vidal (ORCID: https://orcid.org/0000-0002-8915-0683)
- Keith Tolley (ORCID: https://orcid.org/0000-0001-9732-2994)
Institutions
- HSE Science and Research Centre (GB)
- Financial Network Analytics (United Kingdom) (GB)
- Hospital Clínic de Barcelona (ES)
- Mundipharma (United Kingdom) (GB)
- Buxton Hospital (GB)
- Helios Vogtland Klinikum Plauen (DE)
Publication Details
- Journal
- Mycoses
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1111/myc.70148
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00